PATENT CLAIM ANALYSIS

Application Number: 15885942
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["424", "186100"]

Abstract:
A composition for use in inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus including an isolated nucleic acid encoding a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, an isolated nucleic acid sequence encoding a first guide RNA (gRNA) having a first spacer sequence that is complementary to a first target protospacer sequence in a proviral DNA, and an isolated nucleic acid sequence encoding a second gRNA having a second spacer sequence that is complementary to a second target protospacer sequence in the proviral DNA, wherein said first target protospacer sequence and said second target protospacer sequence are situated in a long terminal repeat (LTR) of the proviral DNA. A pharmaceutical composition for use in inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus.

Claim (Index 16):
The pharmaceutical composition of  claim 13 , wherein said composition is formulated for topical application.

Metadata:
- Claim Count in Document: 74.0
- Percentile: 88.0
- Lexical Diversity: 2.42857
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14838057', '15148261', '15430218', '15864309', '15250514']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7715862039917837
- 35 USC 102 Novelty (BERT): 0.5789719667357107
- Combined Prediction Score: 0.7523247802661764
- Mean Citation Score: 493.964416
- Max Citation Score: 694.1721
- Similarity Product: 368.67950188191526

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test